Chieko Yoshida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chieko Yoshida has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Hidenori Ichiyasu
Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan
3 shared publications - Hirotsugu Kohrogi
Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, Japan
3 shared publications - Susumu Hirosako
Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan
3 shared publications - Hideharu Ideguchi
Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan
2 shared publications Hidenori Ichiyasu
Department of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
2 shared publications- Keisuke Kojima
Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan
2 shared publications
Latest Publications
- Open Access
- 21 January 2022
- Published by Elsevier in Allergology International
- Vol. 71 (2) , 259-261
Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis
- 21 January 2022
- Published by Elsevier in Allergology International
- Vol. 71 (2) , 259-261
Open AccessSuccessful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Predicting daily physical activity with using 6MWT in patients with chronic interstitial lung diseases
Background: Physical activity (PA) is defined as any bodily movement produced by skeletal muscles that requires energy expenditure. PA is well known as one of predictors of individual prognosis in chronic respiratory diseases. An accelerometer which is expensive is required for objective assessment of PA. Six-minute walk test (6MWT) which is inexpensive and simple is known for the well-established and reliable surrogate marker to know about exercise capacity in various respiratory diseases. Objectives: To evaluate if PA can be predicted by 6-minute walk distance (6MWD) in patients with chronic interstitial lung disease (ILD). Methods: Prospective observational study was conducted from 2013 to 2016 at Kumamoto University Hospital in Japan. Stable chronic ILD patients were included. Physical activity level (PAL) and steps per day were quantified by using the accelerometer (Kenz Lifecorder GS; Suzuken Co. Ltd., Nagoya). Participants were examined 6MWT and pulmonary function test at the same time. Results: Thirty-six individuals with chronic ILD participated. The underlying diseases were Interstitial pulmonary fibrosis, chronic hypersensitivity pneumonia, connective tissue diseases-associated ILD, combined pulmonary fibrosis and emphysema, and others. PAL and steps per day were significantly correlated with 6MWD (r=0.413, p< 0.012 and r=0.397, p<0.016 respectively). Using ROC curve for identifying the very inactive patients (PAL < 1.40), 6MWD=418m was the best cut-off point, yielding a 68.4% sensitivity and 65.7% specificity (AUC=0.706). Conclusion: 6MWD can predict physical inactivity in patients with chronic ILD patients.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Predicting daily physical activity with using 6MWT in patients with chronic interstitial lung diseases
Background: Physical activity (PA) is defined as any bodily movement produced by skeletal muscles that requires energy expenditure. PA is well known as one of predictors of individual prognosis in chronic respiratory diseases. An accelerometer which is expensive is required for objective assessment of PA. Six-minute walk test (6MWT) which is inexpensive and simple is known for the well-established and reliable surrogate marker to know about exercise capacity in various respiratory diseases. Objectives: To evaluate if PA can be predicted by 6-minute walk distance (6MWD) in patients with chronic interstitial lung disease (ILD). Methods: Prospective observational study was conducted from 2013 to 2016 at Kumamoto University Hospital in Japan. Stable chronic ILD patients were included. Physical activity level (PAL) and steps per day were quantified by using the accelerometer (Kenz Lifecorder GS; Suzuken Co. Ltd., Nagoya). Participants were examined 6MWT and pulmonary function test at the same time. Results: Thirty-six individuals with chronic ILD participated. The underlying diseases were Interstitial pulmonary fibrosis, chronic hypersensitivity pneumonia, connective tissue diseases-associated ILD, combined pulmonary fibrosis and emphysema, and others. PAL and steps per day were significantly correlated with 6MWD (r=0.413, p< 0.012 and r=0.397, p<0.016 respectively). Using ROC curve for identifying the very inactive patients (PAL < 1.40), 6MWD=418m was the best cut-off point, yielding a 68.4% sensitivity and 65.7% specificity (AUC=0.706). Conclusion: 6MWD can predict physical inactivity in patients with chronic ILD patients.
- 1 July 2019
- Published by Elsevier in Respiratory Investigation
- Vol. 57 (4) , 368-375
Four-meter gait speed predicts daily physical activity in patients with chronic respiratory diseases
- 1 July 2019
- Published by Elsevier in Respiratory Investigation
- Vol. 57 (4) , 368-375
Four-meter gait speed predicts daily physical activity in patients with chronic respiratory diseases
- Open Access
- 24 October 2017
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 17 (1) , 1-10
Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias
Rapidly progressive interstitial pneumonias (RPIPs) associated with clinically amyopathic dermatomyositis (CADM) are highly resistant to therapy and have a poor prognosis. Multimodal therapies, including direct hemoperfusion using a polymyxin B-immobilized fiber column (PMX-DHP), have a protective effect on RPIPs. We evaluated the effects of PMX-DHP on CADM-associated RPIPs. We retrospectively enrolled 14 patients with CADM-associated RPIPs and acute respiratory failure treated with PMX-DHP, corticosteroids, and immunosuppressive agents. Clinical manifestations were compared between survivors and non-survivors at 90 days after PMX-DHP. The survival rate at 90 days after PMX-DHP was 35.7% (5/14). Before PMX-DHP, the survivor group exhibited a significantly higher PaO2/FiO2 (P/F) ratio and serum surfactant protein-D (SP-D) levels and significantly lower lactate dehydrogenase (LDH) and ferritin levels than the non-survivor group. Platelet counts were significantly decreased after PMX-DHP therapy in both groups, but remained higher in the survivor group than the non-survivor group over the course of treatment. Anti-melanoma differentiation-associated gene 5 (MDA-5) antibody positive patients demonstrated a poor 90-day survival rate, lower platelet counts and P/F ratio, and higher LDH levels than anti-MDA-5 antibody negative patients. CADM-associated RPIPs with anti-MDA-5 antibody is associated with a very poor prognosis. A higher P/F ratio and SP-D level, lower LDH and ferritin levels, higher platelet counts, and anti-MDA-5 antibody negativity are important prognostic markers in patients with CADM-associated RPIPs treated with PMX-DHP.
- 24 October 2017
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 17 (1) , 1-10
Open AccessClinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias
Rapidly progressive interstitial pneumonias (RPIPs) associated with clinically amyopathic dermatomyositis (CADM) are highly resistant to therapy and have a poor prognosis. Multimodal therapies, including direct hemoperfusion using a polymyxin B-immobilized fiber column (PMX-DHP), have a protective effect on RPIPs. We evaluated the effects of PMX-DHP on CADM-associated RPIPs. We retrospectively enrolled 14 patients with CADM-associated RPIPs and acute respiratory failure treated with PMX-DHP, corticosteroids, and immunosuppressive agents. Clinical manifestations were compared between survivors and non-survivors at 90 days after PMX-DHP. The survival rate at 90 days after PMX-DHP was 35.7% (5/14). Before PMX-DHP, the survivor group exhibited a significantly higher PaO2/FiO2 (P/F) ratio and serum surfactant protein-D (SP-D) levels and significantly lower lactate dehydrogenase (LDH) and ferritin levels than the non-survivor group. Platelet counts were significantly decreased after PMX-DHP therapy in both groups, but remained higher in the survivor group than the non-survivor group over the course of treatment. Anti-melanoma differentiation-associated gene 5 (MDA-5) antibody positive patients demonstrated a poor 90-day survival rate, lower platelet counts and P/F ratio, and higher LDH levels than anti-MDA-5 antibody negative patients. CADM-associated RPIPs with anti-MDA-5 antibody is associated with a very poor prognosis. A higher P/F ratio and SP-D level, lower LDH and ferritin levels, higher platelet counts, and anti-MDA-5 antibody negativity are important prognostic markers in patients with CADM-associated RPIPs treated with PMX-DHP.